Integrated analysis of dynamic FET PET/CT parameters, histology, and methylation profiling of 44 gliomas
暂无分享,去创建一个
M. Röhrich | K. Huang | D. Schrimpf | N. Albert | T. Hielscher | A. von Deimling | U. Schüller | A. Dimitrakopoulou-Strauss | U. Haberkorn | Kristin Huang
[1] K. Hamacher,et al. O-(2-[18F]fluorethyl)-L-tyrosine PET in the clinical evaluation of primary brain tumours , 2005, European Journal of Nuclear Medicine and Molecular Imaging.
[2] Karl-Josef Langen,et al. O-(2-[18F]fluoroethyl)-L-tyrosine PET combined with MRI improves the diagnostic assessment of cerebral gliomas. , 2005, Brain : a journal of neurology.
[3] Jochen Herms,et al. FET PET for the evaluation of untreated gliomas: correlation of FET uptake and uptake kinetics with tumour grading , 2007, European Journal of Nuclear Medicine and Molecular Imaging.
[4] B. Scheithauer,et al. The 2007 WHO classification of tumours of the central nervous system , 2007, Acta Neuropathologica.
[5] C. Boy,et al. The quantification of dynamic FET PET imaging and correlation with the clinical outcome in patients with glioblastoma , 2009, Physics in medicine and biology.
[6] Xavier Robin,et al. pROC: an open-source package for R and S+ to analyze and compare ROC curves , 2011, BMC Bioinformatics.
[7] Peter Dalgaard,et al. R Development Core Team (2010): R: A language and environment for statistical computing , 2010 .
[8] R. Baum,et al. Dynamic O-(2-[18F]fluoroethyl)-L-tyrosine (F-18 FET) PET for Glioma Grading: Assessment of Individual Probability of Malignancy , 2011, Clinical nuclear medicine.
[9] A. von Deimling,et al. Hot spots in dynamic (18)FET-PET delineate malignant tumor parts within suspected WHO grade II gliomas. , 2011, Neuro-oncology.
[10] Kirsten Schmieder,et al. Pharmacokinetic Studies of 68Ga-Labeled Bombesin (68Ga-BZH3) and F-18 FDG PET in Patients With Recurrent Gliomas and Comparison to Grading: Preliminary Results , 2011, Clinical nuclear medicine.
[11] J. Tonn,et al. MRI-suspected low-grade glioma: is there a need to perform dynamic FET PET? , 2012, European Journal of Nuclear Medicine and Molecular Imaging.
[12] Paul Cumming,et al. Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas. , 2012, Neuro-oncology.
[13] David T. W. Jones,et al. Hotspot mutations in H3F3A and IDH1 define distinct epigenetic and biological subgroups of glioblastoma. , 2012, Cancer cell.
[14] Matthew J. Betts,et al. Dissecting the genomic complexity underlying medulloblastoma , 2012, Nature.
[15] Thomas Beez,et al. Diagnostic Performance of 18F-FET PET in Newly Diagnosed Cerebral Lesions Suggestive of Glioma , 2013, The Journal of Nuclear Medicine.
[16] Gereon R Fink,et al. Role of O-(2-18F-Fluoroethyl)-l-Tyrosine PET as a Diagnostic Tool for Detection of Malignant Progression in Patients with Low-Grade Glioma , 2013, The Journal of Nuclear Medicine.
[17] Martin Sill,et al. Integrated DNA methylation and copy-number profiling identify three clinically and biologically relevant groups of anaplastic glioma , 2014, Acta Neuropathologica.
[18] David T. W. Jones,et al. ATRX and IDH1-R132H immunohistochemistry with subsequent copy number analysis and IDH sequencing as a basis for an “integrated” diagnostic approach for adult astrocytoma, oligodendroglioma and glioblastoma , 2014, Acta Neuropathologica.
[19] Uwe Haberkorn,et al. Intra-individual comparison of ¹⁸F-FET and ¹⁸F-DOPA in PET imaging of recurrent brain tumors. , 2014, Neuro-oncology.
[20] P. Bartenstein,et al. Dynamic 18F-FET PET in Newly Diagnosed Astrocytic Low-Grade Glioma Identifies High-Risk Patients , 2014, The Journal of Nuclear Medicine.
[21] U. Haberkorn,et al. Intra-individual comparison of 18 F-FET and 18 F-DOPA in PET imaging of recurrent brain tumors , 2014 .
[22] N. Galldiks,et al. From the clinician's point of view - What is the status quo of positron emission tomography in patients with brain tumors? , 2015, Neuro-oncology.
[23] N. Albert,et al. Early static 18F-FET-PET scans have a higher accuracy for glioma grading than the standard 20–40 min scans , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[24] Pieter Wesseling,et al. IDH mutant diffuse and anaplastic astrocytomas have similar age at presentation and little difference in survival: a grading problem for WHO , 2015, Acta Neuropathologica.
[25] Stefan Förster,et al. Textural analysis of pre-therapeutic [18F]-FET-PET and its correlation with tumor grade and patient survival in high-grade gliomas , 2015, European Journal of Nuclear Medicine and Molecular Imaging.
[26] G. Reifenberger,et al. The 2016 World Health Organization Classification of Tumors of the Central Nervous System: a summary , 2016, Acta Neuropathologica.
[27] Ian Law,et al. Response Assessment in Neuro-Oncology working group and European Association for Neuro-Oncology recommendations for the clinical use of PET imaging in gliomas. , 2016, Neuro-oncology.
[28] John O. Prior,et al. Performance of 18F-FET versus 18F-FDG-PET for the diagnosis and grading of brain tumors: systematic review and meta-analysis. , 2016, Neuro-oncology.
[29] G. Reifenberger,et al. Advances in the molecular genetics of gliomas — implications for classification and therapy , 2017, Nature Reviews Clinical Oncology.
[30] Gereon R Fink,et al. Static and dynamic 18F–FET PET for the characterization of gliomas defined by IDH and 1p/19q status , 2018, European Journal of Nuclear Medicine and Molecular Imaging.
[31] F. Mottaghy,et al. Imaging of amino acid transport in brain tumours: Positron emission tomography with O-(2-[18F]fluoroethyl)-L-tyrosine (FET). , 2017, Methods.
[32] Martin Sill,et al. DNA methylation-based classification and grading system for meningioma: a multicentre, retrospective analysis. , 2017, The Lancet. Oncology.
[33] N. Samadi,et al. Comparison of genome‐wide analysis techniques to DNA methylation analysis in human cancer , 2018, Journal of cellular physiology.
[34] Armin Giese,et al. Identification of time-to-peak on dynamic 18F-FET-PET as a prognostic marker specifically in IDH1/2 mutant diffuse astrocytoma , 2018, Neuro-oncology.
[35] David T. W. Jones,et al. Epithelioid glioblastomas stratify into established diagnostic subsets upon integrated molecular analysis , 2018, Brain pathology.
[36] M. Hegi,et al. Glioma epigenetics: From subclassification to novel treatment options. , 2017, Seminars in cancer biology.